Zydus Lifesciences Limited, including its subsidiaries and affiliates (“Zydus”), has entered into an agreement with Agenus Inc. (NASDAQ: AGEN) to acquire the commercial rights for its investigational Botensilimab (BOT) and Balstilimab (BAL), combination therapy.
Agenus is a clinical-stage immuno-oncology company focused on developing immune therapies for cancer treatment. The BOT/BAL combination is an immunotherapy currently in advanced clinical trials. It has shown clinical activity in studies involving over 1,200 patients with nine different types of cancer, in both late-stage and neoadjuvant treatment settings.
Under the agreement, Zydus will handle clinical development and regulatory approvals for BOT/BAL in India and Sri Lanka. Upon successful approval and commercialization, Zydus will pay Agenus a 5% royalty on net sales.
Zydus will also work on expanding the use of BOT/BAL beyond its initial indications to other areas with unmet medical needs and earlier treatment stages, including neoadjuvant therapy.
